Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/48342| Title: | Targeting EBV is a viable therapeutic strategy in MS: No | Authors: | HELLINGS, Niels | Issue Date: | 2026 | Publisher: | SAGE PUBLICATIONS LTD | Source: | Multiple Sclerosis Journal, | Status: | Early view | Notes: | Hellings, N (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Neuroimmune Connect & Repair NIC&R Lab, Martelarenlaan 42, B-3500 Hasselt, Belgium. niels.hellings@uhasselt.be |
Document URI: | http://hdl.handle.net/1942/48342 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | DOI: | 10.1177/13524585251409970 | ISI #: | 001662884400001 | Rights: | The Author(s), 2026. Article reuse guidelines: sagepub.com/journalspermissions | Category: | A2 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 13524585251409970.pdf Restricted Access | Early view | 115.06 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.